415 related articles for article (PubMed ID: 18650500)
41. [Too positive comment on glitazones].
Lindberg M
Ugeskr Laeger; 2007 Feb; 169(8):733; author reply 733. PubMed ID: 17338040
[No Abstract] [Full Text] [Related]
42. Future directions for insulin sensitizers in disease prevention.
Colca JR
Curr Opin Investig Drugs; 2007 Sep; 8(9):707-10. PubMed ID: 17729181
[No Abstract] [Full Text] [Related]
43. Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects.
Pfützner A; Weber MM; Forst T
Expert Opin Pharmacother; 2007 Aug; 8(12):1985-98. PubMed ID: 17696799
[TBL] [Abstract][Full Text] [Related]
44. Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes.
Misbin RI
Diabetes Care; 2007 Dec; 30(12):3141-4. PubMed ID: 18042753
[No Abstract] [Full Text] [Related]
45. Pleiotropic effects of thiazolidinediones.
Rizos CV; Liberopoulos EN; Mikhailidis DP; Elisaf MS
Expert Opin Pharmacother; 2008 May; 9(7):1087-108. PubMed ID: 18422468
[TBL] [Abstract][Full Text] [Related]
46. Thiazolidinediones and cardiovascular outcomes in type 2 diabetes.
Singh S; Furberg CD
Heart; 2009 Jan; 95(1):1-3. PubMed ID: 18753156
[No Abstract] [Full Text] [Related]
47. [Glitazone - mailing no 1. In response to DMW 49/2007].
Traut V
Dtsch Med Wochenschr; 2008 Feb; 133(6):261; author reply 262-3. PubMed ID: 18236356
[No Abstract] [Full Text] [Related]
48. The value equation for rosiglitazone and pioglitazone in older persons.
Zarowitz BJ
Geriatr Nurs; 2008; 29(1):9-11. PubMed ID: 18267172
[No Abstract] [Full Text] [Related]
49. [Glitazone - mailing no 3. In response to DMW 49/2007].
Gundel UF
Dtsch Med Wochenschr; 2008 Feb; 133(6):261-2; author reply 262-3. PubMed ID: 18236354
[No Abstract] [Full Text] [Related]
50. [Thiazolidinediones and skeletal health].
Meier C; Bodmer M; Meier CR; Kraenzlin ME
Rev Med Suisse; 2009 Jun; 5(207):1309-10, 1312-3. PubMed ID: 19626930
[TBL] [Abstract][Full Text] [Related]
51. [Glitazones more than hypoglycemics in type 2 diabetes].
Sjöholm A
Lakartidningen; 2007 Oct 24-30; 104(43):3201-3. PubMed ID: 18018938
[No Abstract] [Full Text] [Related]
52. Diabetes drug safety update: Avandia and your heart.
Johns Hopkins Med Lett Health After 50; 2010 Jun; 22(4):1-2, 7. PubMed ID: 20572316
[No Abstract] [Full Text] [Related]
53. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
Krentz A
Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
[TBL] [Abstract][Full Text] [Related]
54. [Heart failure while taking glitazones--what do we know today?].
Halbritter R
Dtsch Med Wochenschr; 2009 Jul; 134(28-29):1488; author reply 1488. PubMed ID: 19572255
[No Abstract] [Full Text] [Related]
55. [Insulin sensitizers is now approved as monotherapy as well. Lowering blood pressure with added effects].
MMW Fortschr Med; 2003 Oct; 145(41):47. PubMed ID: 14655486
[No Abstract] [Full Text] [Related]
56. The rosigliazone meta-analysis: lessons for the future.
Shuster JJ; Schatz DA
Diabetes Care; 2008 Mar; 31(3):e10. PubMed ID: 18308673
[No Abstract] [Full Text] [Related]
57. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
Hemmingsen B; Lund SS; Vaag A
Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
[TBL] [Abstract][Full Text] [Related]
58. Drugs for type 2 diabetes.
Treat Guidel Med Lett; 2011 Aug; 9(108):47-54. PubMed ID: 21778966
[No Abstract] [Full Text] [Related]
59. [Vascular damage decides prognosis of type 2 diabetic patients. Lowering blood glucose is not enough].
MMW Fortschr Med; 2002 May; 144(18):65. PubMed ID: 12422717
[No Abstract] [Full Text] [Related]
60. [Life expectancy decreased by 1/3rd. Who to sink the vascular risk of type 2 diabetic patients?].
MMW Fortschr Med; 2001 Dec; 143(49-50):56. PubMed ID: 11808457
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
